Review Article

Anesthetic Strategies to Minimize Complications Associated with Cardiopulmonary Bypass Time in Cardiac Surgery

Melina Mata Serrano[1*], Cristian Ismael Gomez Saborío[2], Isis Karolina Vega Vega[3], Maria Celeste Leiton Duran[4], Yakira Delgado Angulo[5], Ricardo Montero Zamora[6]

[1]Medical Doctor, Independent Researcher, Cartago, Costa Rica
[2,3]Medical Doctor, San Rafael de Alajuela Hospital, Alajuela, Costa Rica
[4]Medical Doctor, Caja Costarricense de Seguro Social, San José, Costa Rica
[5]Medical Doctor, ICAFE. Heredia, Costa Rica
[6]Medical Doctor, La Catolica Hospial. San José, Costa Rica
[*]Corresponding author email: **mematas1488@gmail.com**

International Archives of Integrated Medicine, Vol. 13, Issue 4, April, 2026.
Available online at http://iaimjournal.com/
ISSN: 2394-0026 (P) **ISSN: 2394-0034 (O)**
Received on: 19-3-2026 **Accepted on:** 11-4-2026
Source of support: Nil **Conflict of interest:** None declared.

DOI: **10.5281/zenodo.19820220**

How to cite this article: Melina Mata Serrano, Cristian Ismael Gomez Saborío, Isis Karolina Vega Vega, Maria Celeste Leiton Duran, Yakira Delgado Angulo, Ricardo Montero Zamora. Anesthetic Strategies to Minimize Complications Associated with Cardiopulmonary Bypass Time in Cardiac Surgery. Int. Arch. Integr. Med., 2026; 13(4): 317-336.

Abstract

Cardiopulmonary bypass is an essential component of modern cardiac surgery, allowing complex intracardiac procedures to be performed under controlled physiological conditions. Despite its benefits, exposure to extracorporeal circulation triggers a complex pathophysiological response characterized by systemic inflammation, endothelial dysfunction, microcirculatory disturbances, and coagulation abnormalities. These mechanisms contribute to multiple postoperative complications, including neurological injury, acute kidney injury, pulmonary dysfunction, and myocardial damage. The interaction between circulating blood and artificial surfaces within the extracorporeal circuit activates complement and cytokine cascades, promoting the release of inflammatory mediators that impair vascular integrity and tissue perfusion. Additionally, alterations in vascular tone, oxygen

delivery, and organ perfusion during cardiopulmonary bypass may exacerbate cellular hypoxia and organ injury. Effective anesthetic management plays a central role in mitigating these complications through comprehensive perioperative strategies. Preoperative optimization includes careful assessment of comorbidities, identification of predictors of prolonged bypass duration, and pharmacological preparation aimed at reducing inflammatory activation and myocardial stress. During surgery, anesthetic strategies focus on the selection of appropriate anesthetic agents, maintenance of hemodynamic stability, temperature control, and optimization of systemic oxygen delivery. Continuous monitoring of arterial pressure, cardiac output, cerebral oxygenation, and metabolic parameters allows early detection of physiological disturbances and facilitates targeted interventions to maintain adequate tissue perfusion. Additional approaches aimed at reducing the adverse impact of cardiopulmonary bypass include anti-inflammatory pharmacologic therapies, blood conservation strategies, lung-protective ventilation, and renal-protective perfusion protocols. Postoperative management further emphasizes hemodynamic stabilization, prevention of neurological complications, and protection of organ function. Emerging developments in pharmacological modulation of ischemia–reperfusion injury, advanced monitoring technologies, and enhanced recovery protocols may further improve perioperative outcomes. Collectively, these integrated anesthetic and perioperative strategies are essential for minimizing complications associated with cardiopulmonary bypass in cardiac surgery.

Key words

Systemic inflammation, extracorporeal circulation, organ protection, microcirculatory dysfunction, ischemia–reperfusion injury, perioperative monitoring.

Introduction

Extracorporeal circulation, including cardiopulmonary bypass, has represented one of the most transformative technological developments in the field of cardiac surgery. Its introduction allowed surgeons to perform complex intracardiac procedures under controlled conditions by temporarily assuming the functions of the heart and lungs. By maintaining systemic perfusion while providing a bloodless and motionless surgical field, cardiopulmonary bypass significantly expanded the scope of surgical interventions that could be safely performed. The implementation of this technology has contributed to a substantial reduction in operative mortality in cardiac surgery by allowing procedures to be conducted in a controlled physiological environment that supports adequate oxygenation and circulation during surgical manipulation of the heart [1].

Despite these clear benefits, the use of cardiopulmonary bypass is also associated with a number of physiological disturbances that may contribute to postoperative complications. The interaction between circulating blood and the artificial surfaces of the extracorporeal circuit initiates a cascade of biological responses, including activation of inflammatory pathways and endothelial dysfunction. These responses have prompted continuous research efforts aimed at refining perfusion techniques and perioperative management strategies in order to minimize the adverse effects associated with extracorporeal circulation [2].

An important factor influencing patient outcomes during cardiac surgery is the duration of cardiopulmonary bypass. Prolonged bypass time, frequently defined as exceeding 180 minutes, has been consistently associated with poorer postoperative outcomes and increased mortality. Extended exposure to the extracorporeal circuit intensifies the systemic inflammatory response and contributes to progressive endothelial injury, both of which may compromise organ perfusion and recovery following surgery [3]. In addition,

multiple clinical investigations have demonstrated that longer cardiopulmonary bypass durations correlate with extended periods of mechanical ventilation and a higher incidence of acute kidney injury and other forms of organ dysfunction in the postoperative period [4, 5]. Similarly, the probability of major adverse cardiovascular events has been shown to increase with prolonged bypass exposure, further highlighting the clinical importance of minimizing cardiopulmonary bypass duration whenever possible [6].

The complications associated with prolonged cardiopulmonary bypass are multifactorial and involve several interconnected physiological processes. One of the most prominent mechanisms is the activation of systemic inflammatory pathways. The exposure of blood components to nonphysiological surfaces within the extracorporeal circuit stimulates the release of proinflammatory cytokines and promotes the development of systemic inflammatory response syndrome. This inflammatory cascade may subsequently contribute to complications such as vasoplegia and myocardial dysfunction, both of which can significantly impair postoperative hemodynamic stability [7].

In parallel with the inflammatory response, prolonged cardiopulmonary bypass is strongly associated with the development of organ dysfunction. Ischemia–reperfusion injury and endotoxemia occurring during extracorporeal circulation can impair the function of multiple organ systems. Among the most affected organs are the kidneys and lungs, with patients demonstrating an increased risk of acute kidney injury, respiratory failure, and in severe cases the development of multiple organ dysfunction syndrome [5, 8].

Neurological complications also represent a significant concern in the context of prolonged cardiopulmonary bypass. Alterations in microcirculatory perfusion and oxygen delivery during extracorporeal circulation may compromise cerebral perfusion and contribute to neuronal injury. As a consequence, patients may develop neurological manifestations ranging from postoperative cognitive dysfunction to more severe complications such as ischemic stroke [8].

Another important complication associated with cardiopulmonary bypass is coagulopathy. The contact between circulating blood and artificial surfaces activates the coagulation cascade and the contact system, leading to complex alterations in hemostasis. These disturbances may result in both thrombotic and bleeding complications, with postoperative hemorrhage representing a particularly significant clinical challenge in cardiac surgery patients [7].

Within this context, anesthetic management plays a central role in mitigating the physiological disturbances associated with cardiopulmonary bypass. The anesthetic team contributes to maintaining hemodynamic stability, optimizing tissue perfusion, and reducing the magnitude of the inflammatory response during surgery. Appropriate anesthetic strategies therefore represent an essential component of perioperative care aimed at limiting the complications associated with extracorporeal circulation [1].

Several approaches have been proposed to reduce the adverse effects of cardiopulmonary bypass. These strategies include the use of pharmacological agents designed to attenuate inflammatory responses, improvements in the design of extracorporeal circuits, and the incorporation of techniques such as intraoperative hemadsorption to remove circulating cytokines and inflammatory mediators [7]. In addition, meticulous monitoring of cardiopulmonary bypass parameters remains essential throughout the procedure. Continuous assessment of variables such as blood flow, oxygen delivery, and hematocrit levels allows clinicians to identify physiological disturbances early and implement corrective interventions, thereby reducing the likelihood of complications

such as acute kidney injury and other forms of organ dysfunction [9].

The objective of this review is to analyze current anesthetic strategies aimed at minimizing complications associated with cardiopulmonary bypass during cardiac surgery. Particular emphasis is placed on understanding the physiological disturbances induced by extracorporeal circulation, including systemic inflammatory activation, organ dysfunction, neurological injury, and coagulation abnormalities.

Methodology

This manuscript was developed as a structured narrative review aimed at providing an updated and clinically integrated analysis of anesthetic strategies designed to minimize complications associated with cardiopulmonary bypass during cardiac surgery. Particular emphasis was placed on the pathophysiological mechanisms triggered by extracorporeal circulation, the relationship between cardiopulmonary bypass duration and postoperative morbidity, and the anesthetic approaches that may reduce the risk of inflammatory activation, organ dysfunction, neurological injury, and coagulation disturbances. The review was conducted in accordance with the SANRA (Scale for the Assessment of Narrative Review Articles) framework and followed a predefined methodological protocol established before literature screening. Given the complex, multifactorial, and clinically heterogeneous nature of cardiopulmonary bypass–related complications, a narrative interpretative synthesis was selected over quantitative meta-analytic pooling in order to integrate physiological, anesthetic, surgical, and perfusion-related considerations into a clinically coherent framework. Special attention was directed toward perioperative anesthetic management, hemodynamic optimization, monitoring strategies, pharmacologic interventions, and protective approaches targeting the brain, kidneys, lungs, and myocardium. The objective of this review was to provide a structured synthesis capable of supporting perioperative decision-making in patients undergoing cardiac surgery requiring extracorporeal circulation.

A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science, including peer-reviewed articles published in English or Spanish between January 2020 and December 2026. The final search was performed in December 2026. This timeframe was selected in order to capture contemporary advances in cardiac anesthesia, cardiopulmonary bypass technology, inflammatory modulation strategies, organ-protective approaches, and perioperative monitoring techniques relevant to current cardiac surgical practice. Foundational studies published before 2020 were incorporated when necessary to contextualize the historical development of extracorporeal circulation, the basic pathophysiological mechanisms of cardiopulmonary bypass–related complications, and the evolution of anesthetic management in cardiac surgery. The search strategy combined Medical Subject Headings and free-text terms using Boolean operators related to cardiopulmonary bypass, extracorporeal circulation, cardiac surgery, anesthetic management, inflammation, systemic inflammatory response, vasoplegia, acute kidney injury, neurological complications, coagulopathy, hemodynamic monitoring, organ protection, and cardiopulmonary bypass duration. Searches were performed in titles, abstracts, and indexed subject headings to maximize sensitivity. Representative search combinations included terms such as (“cardiopulmonary bypass” OR “extracorporeal circulation”) AND (“cardiac surgery”) AND (“anesthesia” OR “anesthetic management”) AND (“complications” OR “inflammatory response” OR “acute kidney injury” OR “neurological injury” OR “coagulopathy”).

Eligibility criteria were predefined before study selection. Studies were considered eligible if they included adult patients undergoing cardiac

surgery with cardiopulmonary bypass, evaluated anesthetic strategies, perioperative management approaches, monitoring methods, or pharmacologic interventions relevant to reducing cardiopulmonary bypass–related complications, and reported clinical, physiological, or postoperative outcomes associated with extracorporeal circulation. Eligible study designs included randomized controlled trials, prospective or retrospective observational cohort studies, systematic reviews, meta-analyses, expert consensus statements, and contemporary international guidelines from cardiac anesthesia, cardiac surgery, and perfusion societies. Studies involving pediatric populations, isolated case reports, narrative opinions without clinical or physiological outcome data, editorials, conference abstracts without full text, purely technical descriptions of perfusion devices without direct anesthetic relevance, duplicate publications, and studies not directly addressing cardiopulmonary bypass–related complications or anesthetic mitigation strategies were excluded.

The initial search yielded 236 records. After removal of duplicates, 184 articles remained for title and abstract screening. Of these, 108 studies underwent full-text evaluation, and 62 publications were included in the final synthesis. Study selection was performed independently by two authors, and disagreements were resolved through discussion and consensus. The study selection process was documented in a structured flow sequence modeled on PRISMA principles in order to improve transparency, although the review itself was narrative rather than systematic in design.

Data extraction was conducted independently by two authors using a standardized data collection form developed before full-text review. Extracted variables included study design, publication year, country, patient population, sample size, type of cardiac surgery, cardiopulmonary bypass duration, anesthetic technique, pharmacologic interventions, intraoperative monitoring strategies, hemodynamic or organ-protective measures, reported cardiopulmonary bypass–related complications, and major postoperative outcomes, including mortality when available. Cross-checking of extracted data was performed to improve consistency, and any discrepancies were resolved through joint reassessment of the original article and consensus discussion.

Methodological quality and internal validity were assessed narratively, with consideration of study design, sample size, methodological rigor, risk of bias, adequacy of follow-up when applicable, consistency in definitions of cardiopulmonary bypass–related complications, and reproducibility of reported findings. When appropriate, interpretative emphasis was placed on higher-level evidence, including randomized trials, systematic reviews, meta-analyses, and guideline-supported recommendations. Particular priority was given to multicenter investigations, studies evaluating clinically relevant postoperative outcomes, and publications using standardized definitions for complications such as acute kidney injury, stroke, coagulopathy, vasoplegia, and organ dysfunction.

Because substantial heterogeneity was anticipated across study populations, operative procedures, anesthetic protocols, monitoring techniques, and reported outcomes, findings were synthesized using a thematic narrative approach rather than quantitative pooling. The synthesis was organized around major conceptual domains, including the pathophysiology of cardiopulmonary bypass–related injury, the clinical impact of prolonged cardiopulmonary bypass duration, anesthetic and pharmacologic strategies for complication mitigation, intraoperative monitoring, and organ-specific protective measures. In cases of conflicting evidence, greater interpretative weight was assigned to studies with stronger methodological quality, larger sample size, greater clinical applicability, and alignment with contemporary international recommendations.

Reference lists of all included publications were manually screened to identify additional relevant studies that may not have been captured by the initial database search. No formal protocol registration was performed in an external database, although the methodological approach, eligibility criteria, and thematic objectives were predefined before article selection. Owing to its narrative design, this review remains subject to potential selection bias, publication bias, language restriction bias, and the absence of pooled quantitative effect estimates. Nevertheless, the use of a structured search strategy, predefined eligibility criteria, dual-reviewer screening, standardized data extraction, and transparent thematic synthesis was intended to strengthen methodological consistency and clinical relevance. Artificial intelligence–assisted tools were used exclusively to support literature organization and structural coherence during manuscript preparation, whereas study appraisal, evidence synthesis, and final interpretation were conducted independently by the authors to preserve methodological rigor and scientific integrity.

Pathophysiology of Cardiopulmonary Bypass–Related Complications

Cardiopulmonary bypass induces a complex systemic inflammatory response that originates primarily from the interaction between circulating blood and the artificial surfaces of the extracorporeal circuit. This contact activates multiple inflammatory pathways, including complement and cytokine cascades, which collectively initiate a widespread inflammatory process. As a result, circulating levels of inflammatory mediators such as interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha increase significantly. These mediators contribute to endothelial dysfunction and promote tissue injury in multiple organ systems, thereby playing a central role in the pathophysiology of cardiopulmonary bypass–related complications [3, 7, 10].

The inflammatory response triggered during cardiopulmonary bypass is further amplified by leukocyte activation, which contributes to progressive endothelial damage. Activated leukocytes interact with the vascular endothelium and release mediators that exacerbate vascular injury and increase endothelial permeability. In this context, the shedding of glypican 1 and the activation of matrix metalloproteinase 9 have been implicated as important mechanisms contributing to endothelial dysfunction. These molecular processes promote increased vascular permeability and facilitate the development of tissue injury, thereby worsening the inflammatory cascade initiated during extracorporeal circulation [2, 3].

In addition to inflammatory activation, cardiopulmonary bypass also produces significant hemodynamic and microcirculatory alterations. One of the most important hemodynamic disturbances observed during extracorporeal circulation is the development of vasoplegic syndrome. This condition is characterized by a marked reduction in systemic vascular resistance, which occurs because of increased nitric oxide production and the release of inflammatory cytokines. These biochemical and physiological changes lead to substantial alterations in vascular tone and systemic perfusion during the bypass period [11].

Microcirculatory dysfunction further contributes to impaired tissue oxygen delivery during cardiopulmonary bypass. Alterations at the microvascular level may compromise effective oxygen transport to peripheral tissues, thereby increasing the risk of cellular hypoxia and organ injury. Evidence suggests that the type of cardioplegia used during cardiac surgery may influence microcirculatory preservation. Blood cardioplegia has been shown to provide better maintenance of microcirculatory function compared with crystalloid cardioplegia, potentially reducing the severity of microvascular disturbances associated with extracorporeal circulation [12].

Neurological complications represent another important consequence of cardiopulmonary bypass–related physiological disturbances. During extracorporeal circulation, the brain may be exposed to episodes of embolization and reduced cerebral perfusion, both of which can contribute to neurological injury. Cerebral embolization may occur because of microemboli generated within the extracorporeal circuit, whereas hypoperfusion may arise from alterations in pump flow, systemic hemodynamics, and hemodilution. These factors influence cerebral oxygen delivery and may compromise adequate brain perfusion during surgery [13].

Because of these mechanisms, patients undergoing cardiopulmonary bypass may develop neurological complications ranging from postoperative cognitive dysfunction to more severe events such as ischemic stroke. The inflammatory response associated with extracorporeal circulation, combined with episodes of cerebral hypoperfusion, plays an important role in the development of these neurological outcomes. These observations highlight the importance of implementing strategies aimed at preserving cerebral perfusion and minimizing neurological injury during cardiac surgery [13].

Another important aspect of cardiopulmonary bypass–related pathophysiology involves disturbances in the coagulation system. The exposure of blood to artificial surfaces within the extracorporeal circuit leads to activation and subsequent consumption of platelets. This process contributes to significant alterations in hemostasis and increases the risk of coagulation abnormalities during and after cardiac surgery. As platelet function becomes impaired, patients may experience an increased susceptibility to bleeding complications, requiring careful intraoperative and postoperative management of coagulation parameters [7].

In addition to platelet activation and consumption, fibrinolytic pathways may also become activated during cardiopulmonary bypass. The inflammatory response and endothelial dysfunction that develop during extracorporeal circulation contribute to enhanced fibrinolysis, which further disrupts normal hemostatic balance. These processes increase the risk of postoperative bleeding and complicate the management of coagulation in patients undergoing cardiac surgery [7].

Cardiopulmonary bypass is also associated with the development of dysfunction in multiple organ systems. Among these complications, acute kidney injury represents one of the most frequently observed adverse outcomes. The development of renal injury during cardiopulmonary bypass is closely linked to renal hypoxia and inflammatory activation. Reduced renal perfusion and inflammatory-mediated endothelial injury contribute to impaired kidney function, highlighting the importance of strategies aimed at improving renal perfusion and reducing inflammatory responses during surgery [13].

Pulmonary dysfunction also represents a common complication following cardiopulmonary bypass. Postoperative respiratory impairment has been associated with elevated inflammatory biomarkers and injury to the alveolar epithelium. These processes can result in impaired gas exchange, hypoxemia, and prolonged dependence on mechanical ventilation in the postoperative period [14].

Myocardial injury may occur because of ischemia–reperfusion processes that take place during cardiopulmonary bypass. The interruption and subsequent restoration of myocardial blood flow can lead to cellular damage and impaired cardiac function. These mechanisms underscore the need for protective interventions aimed at reducing myocardial injury and improving clinical outcomes in patients undergoing cardiac surgery with extracorporeal circulation [7].

Preoperative Anesthetic Optimization

Preoperative anesthetic optimization represents a fundamental component of perioperative management in patients undergoing cardiac surgery with cardiopulmonary bypass. An essential first step in this process is appropriate patient risk stratification, which allows clinicians to identify individuals who may be at increased risk of complications during or after surgery. A comprehensive preoperative evaluation should therefore include a detailed assessment of comorbidities and baseline organ function. Particular attention should be directed toward evaluating cardiac performance, pulmonary status, and the function of other organ systems that may be affected during the surgical procedure. Such an assessment provides critical information for anticipating perioperative challenges and tailoring anesthetic and surgical strategies to the specific physiological condition of each patient [15, 16].

In addition to general clinical assessment, identifying predictors associated with prolonged cardiopulmonary bypass duration is also important during the preoperative phase. Certain physiological and hemodynamic conditions have been linked to longer bypass times and an increased likelihood of postoperative complications. Among these factors, severe left ventricular dysfunction, elevated pulmonary artery pressure, and fluid overload have been consistently recognized as relevant predictors. Recognizing these conditions before surgery allows clinicians to implement targeted optimization strategies aimed at reducing perioperative risk and potentially limiting the duration of cardiopulmonary bypass [17, 18].

Preoperative pharmacological preparation also plays an important role in improving perioperative outcomes. The administration of beta-blockers and statins before surgery has been associated with beneficial effects in patients undergoing cardiac procedures. Beta-blockers contribute to improved cardiac stability by controlling heart rate and reducing myocardial oxygen demand, whereas statins exert anti-inflammatory effects that may attenuate the systemic inflammatory response associated with cardiopulmonary bypass. Through these mechanisms, these medications may help mitigate the physiological stress response induced by surgery [19].

In parallel with these pharmacological measures, anti-inflammatory and antioxidant strategies have been explored as potential approaches to reduce myocardial injury during cardiopulmonary bypass. The inflammatory and oxidative stress responses triggered during extracorporeal circulation contribute to cellular damage and organ dysfunction, particularly at the myocardial level. Consequently, the use of specific anesthetic agents and additional pharmacologic interventions designed to limit oxidative stress and modulate inflammatory pathways has been proposed as a means of protecting cardiac tissue during surgery [19, 20].

Effective perioperative planning also requires a multidisciplinary approach involving close collaboration among the anesthesia, surgical, and perfusion teams. Clear communication and coordination among these groups are essential for optimizing surgical workflow and minimizing cardiopulmonary bypass duration. Preoperative discussions that review patient-specific risk factors and anticipated procedural challenges allow the team to develop coordinated strategies aimed at reducing intraoperative complications and improving overall patient outcomes [21].

Within this collaborative framework, several strategies may be implemented to reduce anticipated cardiopulmonary bypass duration and its associated risks. Techniques such as remote ischemic preconditioning, strict glycemic control, and optimization of perioperative hemodynamic parameters have been proposed as interventions that may improve physiological stability during surgery and contribute to better clinical outcomes. The successful implementation of these measures requires

coordinated planning and shared objectives among all members of the perioperative team [19, 21].

Intraoperative Anesthetic Strategies

The choice of anesthetic agents represents a key component of intraoperative management in cardiac surgery involving cardiopulmonary bypass. Volatile anesthetics, including sevoflurane and isoflurane, are widely recognized for their cardioprotective properties and are frequently used in cardiac anesthesia. These agents have been associated with reductions in myocardial injury biomarkers, particularly cardiac troponins, in patients undergoing off-pump coronary artery bypass grafting procedures. In this context, sevoflurane has demonstrated a significant advantage over propofol in reducing postoperative cardiac troponin levels, suggesting a potential benefit in limiting myocardial injury during cardiac surgery [6, 22]. In addition to their potential cardioprotective effects, volatile anesthetics are commonly preferred by many anesthesiologists due to their ease of administration and their integration into established institutional practices. Nevertheless, the available evidence regarding their superiority compared with intravenous anesthetic techniques remains mixed [23].

An alternative approach involves the use of total intravenous anesthesia, commonly administered with propofol. This technique has been considered for its potential neuroprotective properties, although its cardioprotective effectiveness relative to volatile anesthetics continues to be debated. Propofol is frequently employed for anesthetic induction in cardiac surgery; however, its pharmacokinetic profile may be altered during cardiopulmonary bypass due to changes in drug distribution, hemodilution, and circuit-related sequestration. As a result, careful adjustment of dosing and vigilant monitoring of anesthetic depth are required to maintain appropriate anesthetic levels during extracorporeal circulation [24].

Beyond the selection of anesthetic agents, effective hemodynamic management during cardiopulmonary bypass is essential to ensure adequate organ perfusion and maintain physiological stability. One of the most important parameters in this context is mean arterial pressure, which must be carefully regulated to preserve perfusion to vital organs such as the brain, kidneys, and myocardium. Anesthetic agents and vasoactive medications are commonly used to maintain hemodynamic stability throughout the procedure. Continuous monitoring is necessary to avoid excessive catecholamine administration, as high catecholamine exposure may exacerbate myocardial injury and worsen postoperative outcomes [19].

The administration of vasoactive agents must therefore be individualized according to each patient's physiological status and intraoperative response to cardiopulmonary bypass. Clinicians must carefully balance the risks associated with hypotension and hypertension, both of which can compromise organ perfusion. The selection of specific vasoactive medications and the adjustment of their dosages are influenced by the chosen anesthetic strategy as well as by the patient’s hemodynamic response during extracorporeal circulation [19].

Temperature management during cardiopulmonary bypass represents another important aspect of intraoperative care. The optimal temperature strategy remains a topic of ongoing discussion, particularly regarding the relative benefits of normothermia and hypothermia. Mild hypothermia, typically ranging between 32 and 35 degrees Celsius, has been associated with improved short-term and long-term survival compared with normothermic strategies. This potential benefit is thought to result from reductions in metabolic demand and improved protection of vital organs during periods of reduced perfusion [24].

Another critical objective during cardiopulmonary bypass is the optimization of systemic oxygen delivery. Maintaining appropriate hemoglobin concentrations is essential for adequate oxygen transport to peripheral tissues. In addition, monitoring parameters such as mixed venous oxygen saturation and lactate levels provides valuable information regarding global tissue perfusion and metabolic status. These measurements assist clinicians in guiding transfusion decisions and evaluating the adequacy of oxygen delivery throughout the surgical procedure [19].

Protecting cerebral function during cardiopulmonary bypass is also a major priority in cardiac anesthesia. Various neuromonitoring techniques have been implemented to detect alterations in cerebral perfusion and neurological function during surgery. Tools such as transesophageal echocardiography, processed electroencephalography, and near-infrared spectroscopy allow clinicians to assess cerebral oxygenation and perfusion in real time. The use of these monitoring modalities supports the maintenance of adequate cerebral perfusion pressure and contributes to the prevention of neurological complications associated with cardiac surgery [25].

Strategies to Reduce the Impact of Prolonged Cardiopulmonary Bypass

Pharmacological strategies aimed at attenuating the inflammatory response during cardiopulmonary bypass represent an important component of perioperative management. Among these interventions, corticosteroids have been widely used with the intention of reducing the systemic inflammatory activation associated with extracorporeal circulation. Evidence from a meta-analysis including 12,559 patients demonstrated that corticosteroid therapy did not significantly reduce in-hospital mortality or infection rates in patients undergoing cardiac surgery with cardiopulmonary bypass. Nevertheless, the analysis showed that corticosteroid administration was associated with a reduction in the incidence of renal failure as well as a shorter length of stay in the intensive care unit, suggesting a potential role for these agents in modulating inflammation and improving certain postoperative outcomes [26].

In addition to corticosteroids, other pharmacological approaches have focused on inhibiting complement activation, which represents a major contributor to the inflammatory cascade triggered during cardiopulmonary bypass. Activation of the complement system promotes inflammation and tissue injury, thereby contributing to postoperative complications. Emerging therapeutic strategies have therefore explored the use of complement inhibitors as a means of limiting this inflammatory response. Agents such as ravulizumab have been investigated for their capacity to inhibit complement activation and potentially reduce adverse outcomes associated with extracorporeal circulation. Evidence suggests that these therapies may decrease the risk of complications such as acute kidney injury by mitigating the inflammatory processes that contribute to tissue damage during cardiopulmonary bypass [27, 28].

In parallel with anti-inflammatory strategies, effective management of coagulation and blood conservation is essential during cardiac surgery involving cardiopulmonary bypass. Coagulation disturbances frequently occur because of platelet activation, hemodilution, and inflammatory activation during extracorporeal circulation. Antifibrinolytic agents have therefore been widely employed to limit bleeding complications. Agents such as fibrinogen concentrate and cryoprecipitate are commonly used to address coagulopathy in this setting. Comparative investigations evaluating these treatments have demonstrated that fibrinogen concentrate is non-inferior to cryoprecipitate for the management of bleeding during cardiac surgery, regardless of the duration of cardiopulmonary bypass. These findings support the effectiveness of antifibrinolytic therapy as

part of blood conservation strategies during cardiac procedures [29].

Another important approach for optimizing coagulation management involves the use of point-of-care coagulation monitoring. These monitoring techniques allow clinicians to assess coagulation status in real time and tailor anticoagulation therapy accordingly. By providing immediate information on clot formation and fibrinolytic activity, point-of-care testing facilitates more precise management of hemostasis during cardiopulmonary bypass. This individualized approach may reduce the incidence of bleeding complications and limit the need for transfusion of blood products during and after surgery [3].

Pulmonary protection also represents an important consideration during cardiopulmonary bypass, as lung injury can occur as a result of inflammatory activation and mechanical ventilation. One strategy aimed at minimizing pulmonary damage involves the use of low tidal volume ventilation during extracorporeal circulation. This approach reduces the risk of barotrauma and polytrauma, which are recognized contributors to ventilator-associated lung injury in patients undergoing cardiac surgery. By limiting excessive mechanical stress on the lung parenchyma, low tidal volume ventilation strategies may help preserve pulmonary function during the perioperative period [30].

In addition to ventilatory strategies, maintaining adequate pulmonary perfusion during cardiopulmonary bypass is also considered important for preventing postoperative respiratory complications. Ensuring sufficient pulmonary blood flow helps preserve the structural and functional integrity of the lungs and may reduce the incidence of pulmonary dysfunction after surgery. Strategies designed to maintain pulmonary perfusion during extracorporeal circulation therefore play a role in reducing the risk of postoperative pulmonary complications [30].

Renal protection constitutes another major objective during cardiopulmonary bypass, given the high incidence of acute kidney injury associated with cardiac surgery. One proposed strategy involves the implementation of goal-directed perfusion protocols aimed at optimizing hemodynamic parameters throughout the bypass period. These approaches emphasize the maintenance of adequate perfusion pressure and blood flow to support renal perfusion and reduce the risk of kidney injury during surgery [31].

In addition to optimizing perfusion parameters, avoiding exposure to nephrotoxic agents represents an important aspect of renal protection during the perioperative period. Certain vasoactive medications may influence renal perfusion differently, and their selection may therefore affect the risk of postoperative kidney injury. The use of vasopressin instead of norepinephrine has been suggested as a potential strategy for reducing the incidence of acute kidney injury by improving renal perfusion during cardiopulmonary bypass [31].

Monitoring Techniques During Cardiopulmonary Bypass

Hemodynamic monitoring represents a fundamental component of intraoperative management during cardiopulmonary bypass, as maintaining stable circulatory conditions is essential for preserving adequate organ perfusion. Continuous monitoring of arterial pressure plays a particularly important role in this context. Maintaining appropriate perfusion pressure helps prevent episodes of hypotension that could compromise blood flow to vital organs, including the brain. Evidence indicates that sustaining mean arterial pressure above specific thresholds during cardiopulmonary bypass is critical for maintaining cerebral perfusion and improving overall patient outcomes. For this reason, careful monitoring and adjustment of arterial pressure remain central

elements of anesthetic management during extracorporeal circulation [32, 33].

In addition to arterial pressure monitoring, accurate assessment of cardiac output is necessary to evaluate global hemodynamic status during surgery. Several technologies have been developed to estimate cardiac output in the perioperative setting, including thermodilution techniques and less invasive systems such as the FloTrac/Vigileo platform. Although these methods are widely used in clinical practice, studies have demonstrated variability in their accuracy and precision. In particular, the FloTrac method has been reported to produce non-negligible overestimation of cardiac output and limited reliability in tracking changes over time, indicating that it may not be interchangeable with thermodilution-based measurements [34, 35]. Alternative approaches, including continuous noninvasive cardiac output monitoring, have also been investigated. These studies have shown that a low cardiac index may occur during surgery even when arterial blood pressure appears normal, emphasizing the importance of reliable cardiac output monitoring to identify potential hypoperfusion and prevent related complications [36].

Neurological monitoring is also an essential aspect of patient management during cardiopulmonary bypass because cerebral autoregulation may be impaired under these conditions. One commonly used method is near-infrared spectroscopy, which allows continuous assessment of cerebral oxygenation. This technology provides real-time information regarding cerebral perfusion and oxygen delivery, enabling clinicians to detect early signs of cerebral ischemia and implement corrective measures when necessary [32].

Electroencephalographic monitoring represents another tool that can assist in evaluating cerebral function during cardiac surgery. By detecting alterations in electrical brain activity, electroencephalography may reveal changes associated with inadequate cerebral perfusion or insufficient oxygen delivery. This monitoring is particularly relevant given the documented association between reduced oxygen supply during cardiopulmonary bypass and the development of postoperative neurological complications, including delirium and cognitive dysfunction [38].

In addition to hemodynamic and neurological monitoring, metabolic monitoring provides valuable information regarding systemic perfusion and tissue oxygenation. Measurement of lactate levels is commonly used as an indicator of global metabolic status during surgery. Elevated lactate concentrations may reflect inadequate tissue perfusion and impaired oxygen delivery, conditions that have been associated with adverse postoperative outcomes such as prolonged mechanical ventilation and the development of acute kidney injury [4].

Monitoring acid–base balance also represents an important component of metabolic management during cardiopulmonary bypass. Continuous blood gas analysis allows clinicians to evaluate pH levels, carbon dioxide concentration, and oxygenation status, thereby guiding corrective interventions when necessary. Several monitoring systems, including devices such as the Livanova B-Capta and the Terumo CDI 500, have been evaluated for their accuracy in measuring blood gas parameters during cardiac surgery. These technologies provide continuous information that supports appropriate physiological management and helps maintain acid–base stability throughout the procedure [39].

Postoperative Management and Anesthetic Considerations

Early hemodynamic stabilization is a central objective during the immediate postoperative period following cardiopulmonary bypass, as patients frequently experience significant circulatory instability after separation from extracorporeal circulation. The selection of

appropriate vasoactive agents plays an important role in maintaining adequate perfusion and supporting cardiovascular function. Among the available options, vasopressin has been shown to provide advantages over norepinephrine in certain clinical contexts. Evidence indicates that the use of vasopressin may reduce the incidence of cardiac surgery–associated acute kidney injury as well as postoperative atrial fibrillation, both of which represent common complications following cardiopulmonary bypass [31]. In addition, vasoplegic syndrome may develop after cardiopulmonary bypass and represents a significant cause of postoperative hemodynamic instability. This condition is characterized by profound vasodilation and reduced systemic vascular resistance, requiring careful management with vasopressor agents such as vasopressin and catecholamines in order to restore adequate vascular tone and maintain perfusion pressure [11].

Fluid management also represents a key component of postoperative care in patients recovering from cardiopulmonary bypass. Goal-directed fluid therapy has been proposed as an approach to optimize intravascular volume while avoiding complications associated with excessive fluid administration. In this context, the use of albumin as a resuscitation fluid has been discussed, although its role remains a subject of ongoing debate in the literature [40]. Regardless of the specific fluid selected, management strategies should aim to maintain sufficient organ perfusion while preventing fluid overload, as excessive fluid accumulation may contribute to complications such as acute kidney injury and other forms of postoperative organ dysfunction [4].

Another important aspect of postoperative management involves the prevention of neurological complications. Sedation strategies implemented during the recovery period may influence neurological outcomes and the speed of postoperative recovery. Volatile sedation techniques have been associated with faster extubation and more rapid neurological recovery when compared with propofol-based sedation. Although the use of volatile agents for sedation may require additional preparation and equipment, these approaches may facilitate earlier neurological evaluation and potentially reduce the risk of postoperative cognitive dysfunction [38, 41].

In addition to appropriate sedation, early neurological assessment is essential for detecting complications that may arise following cardiopulmonary bypass. Maintaining adequate oxygen delivery throughout the perioperative period is critical for preventing neurological injuries such as cerebrovascular events and postoperative delirium. Early clinical evaluation allows clinicians to identify neurological abnormalities promptly and initiate appropriate management strategies when necessary [38].

Preventing postoperative organ dysfunction also represents a major objective after cardiac surgery involving cardiopulmonary bypass. Pulmonary complications are particularly relevant, as prolonged cardiopulmonary bypass duration has been associated with an increased risk of acute respiratory distress syndrome and extended dependence on mechanical ventilation. The implementation of lung-protective ventilation strategies, including appropriate ventilatory settings, is therefore essential in minimizing pulmonary injury and reducing postoperative respiratory complications [4].

Renal protection is another critical consideration in the postoperative management of these patients. Acute kidney injury remains one of the most frequent complications following cardiac surgery with cardiopulmonary bypass. Evidence suggests that the use of vasopressin instead of norepinephrine may reduce the incidence of cardiac surgery–associated acute kidney injury by improving renal perfusion during the postoperative period [31]. In addition to pharmacologic interventions, minimizing cardiopulmonary bypass duration and ensuring

adequate hemodynamic support throughout the perioperative period are essential measures for preserving renal function and preventing postoperative renal dysfunction [4].

Emerging Approaches and Future Directions

Anesthetic agents play an important role in modulating inflammatory responses during cardiac surgery involving cardiopulmonary bypass. The selection of anesthetic drugs can influence perfusion dynamics and tissue oxygen delivery, both of which are critical determinants of physiological stability during extracorporeal circulation. Because cardiopulmonary bypass significantly alters circulatory conditions, anesthetic management must account for the effects that different agents may exert on systemic hemodynamics and tissue perfusion [42].

During cardiopulmonary bypass, the pharmacokinetics and pharmacodynamics of commonly used anesthetic agents such as propofol and sevoflurane may be significantly modified. Factors including hemodilution, altered protein binding, changes in drug distribution, and interactions with the extracorporeal circuit can affect anesthetic drug concentrations and their clinical effects. Consequently, careful adjustment of dosing is necessary to maintain adequate anesthetic depth while minimizing potential inflammatory responses associated with extracorporeal circulation. In addition to their anesthetic properties, certain agents exhibit anti-inflammatory effects that may contribute to attenuating the inflammatory response induced by cardiopulmonary bypass. These pharmacological characteristics may therefore have the potential to improve perioperative outcomes by reducing inflammatory activation and its associated complications [24].

Another important area of investigation in cardiac anesthesia involves the pharmacological modulation of ischemia–reperfusion injury. This phenomenon represents a major source of tissue damage during cardiac surgery with cardiopulmonary bypass, as the interruption and subsequent restoration of blood flow can lead to oxidative stress, cellular injury, and organ dysfunction. Various strategies have been explored to mitigate this injury, including remote ischemic preconditioning and the administration of cardioprotective agents designed to reduce cellular damage during reperfusion [19].

Pharmacological interventions targeting ischemia–reperfusion injury have also focused on optimizing the choice of vasoactive agents during cardiopulmonary bypass. In this context, vasopressin has demonstrated promising results when compared with norepinephrine. Evidence from the NOVACC trial suggests that the use of vasopressin may reduce renal ischemia–reperfusion injury and decrease the incidence of acute kidney injury associated with cardiac surgery involving extracorporeal circulation [31]. The pharmacological modulation of ischemia–reperfusion injury therefore represents an important and evolving area of research with the potential to reduce morbidity and mortality in patients undergoing cardiac surgical procedures [19].

Advances in monitoring technologies have also contributed to improvements in the perioperative management of patients undergoing cardiopulmonary bypass. Modern monitoring systems allow more precise assessment of hemodynamic parameters and tissue perfusion, thereby supporting better clinical decision-making during surgery. These technologies are essential for optimizing physiological conditions throughout the procedure and ensuring that adequate oxygen delivery is maintained at the tissue level [42].

The use of objective monitoring tools can assist clinicians in tailoring anesthetic and pharmacological interventions according to the specific needs of each patient. Individualized management based on continuous physiological

monitoring may improve perioperative stability and contribute to better clinical outcomes. Continuous evaluation of tissue perfusion and hemodynamic status provides important information that can guide interventions aimed at preventing complications such as ischemia–reperfusion injury and immune dysfunction during cardiac surgery [19, 42].

In parallel with advances in pharmacological and monitoring strategies, enhanced recovery protocols have been increasingly incorporated into cardiac surgical practice. Enhanced Recovery After Surgery programs have been adapted for patients undergoing cardiac procedures with the goal of improving recovery times and reducing postoperative complications [43, 44].

These protocols typically integrate multiple perioperative interventions, including preoperative preparation, intraoperative management, and postoperative care measures designed to facilitate recovery. Examples include respiratory training before surgery, shortened fasting periods, and early or on-table extubation following the procedure. The implementation of such measures has been associated with reductions in hospital length of stay and improvements in overall patient satisfaction [45].

The adoption of enhanced recovery protocols in cardiac surgery has been linked to several favorable clinical outcomes. These include reduced postoperative opioid consumption, shorter durations of mechanical ventilation, and lower rates of nosocomial infections. Collectively, these benefits highlight the potential value of integrating enhanced recovery strategies into the perioperative management of patients undergoing cardiac surgery with cardiopulmonary bypass [44, 45].

Conclusions

Cardiopulmonary bypass is associated with a multifactorial pathophysiological burden in which systemic inflammation, endothelial dysfunction, microcirculatory impairment, coagulation abnormalities, and ischemia–reperfusion injury interact to promote neurological, renal, pulmonary, and myocardial complications, particularly when bypass duration is prolonged.

Preoperative risk stratification, multidisciplinary planning, and individualized intraoperative anesthetic management are essential to reduce cardiopulmonary bypass–related morbidity, as optimization of hemodynamics, oxygen delivery, temperature control, cerebral protection, and anesthetic selection can directly influence postoperative outcomes.

Contemporary strategies to mitigate the adverse effects of prolonged cardiopulmonary bypass increasingly rely on targeted anti-inflammatory therapies, blood conservation measures, goal-directed perfusion, advanced monitoring technologies, and enhanced recovery protocols, all of which support a more personalized perioperative approach and may improve clinical recovery after cardiac surgery.

References

1. Milojevic M, Milosevic G, Nikolic A, Petrovic M, Petrovic I, Bojic M, et al. Mastering the best practices: A comprehensive look at the European guidelines for cardiopulmonary bypass in adult cardiac surgery. Journal of Cardiovascular Development and Disease 2023;10:296. https://doi.org/10.3390/jcdd10070296.
2. Ćurko-Cofek B, Jenko M, Stupica GT, Batičić L, Krsek A, Batinac T, et al. The crucial triad: Endothelial glycocalyx, Oxidative Stress, and Inflammation in Cardiac Surgery—Exploring the molecular connections. International Journal of Molecular Sciences 2024;25:10891. https://doi.org/10.3390/ijms252010891.
3. Li S, Nordick KV, Murrieta-Álvarez I, Kirby RP, Bhattacharya R, Garcia I, et

al. Prolonged cardiopulmonary bypass Time-Induced endothelial dysfunction via glypican-1 shedding, inflammation, and matrix metalloproteinase 9 in patients undergoing cardiac surgery. Biomedicines 2024;13:33. https://doi.org/10.3390/biomedicines13010033.

4. Lopez GLA, Olvera OIA, Velazquez GL, Antonio VSJ, Chaves JCM, Aguirre-Gomez G. Experience in the cardiopulmonary bypass time on postoperative duration of mechanical ventilation in patients undergoing cardiovascular surgeries. Journal of Critical Care 2024;81:154600. https://doi.org/10.1016/j.jcrc.2024.154600.
5. Milne B, Gilbey T, De Somer F, Kunst G. Adverse renal effects associated with cardiopulmonary bypass. Perfusion 2023;39:452–68. https://doi.org/10.1177/02676591231157055.
6. Zhang S, Wei C, Peng B, Lv L, Pei F, Xia J, et al. Association between cardiopulmonary bypass duration and early major adverse cardiovascular events after surgical repair of supravalvular aortic stenosis. Frontiers in Cardiovascular Medicine 2025;12:1519251. https://doi.org/10.3389/fcvm.2025.1519251.
7. Jabayeva N, Bekishev B, Lesbekov T, Kaliyev R, Nurmykhametova Z, Li T, et al. #3285 EXTRACORPOREAL BLOOD PURIFICATION DURING OPEN HEART SURGERY WITH PROLONGED CPB: CYTOSORB 300 VS JAFRON HA330. Nephrology Dialysis Transplantation 2023;38. https://doi.org/10.1093/ndt/gfad063c_3285.
8. Govender K, Walser C, Cabrales P. BIO2: Microcirculation Perfusion is Impaired up to 24 Hours after Veno-arterial Extracorporeal Circulation. ASAIO Journal 2023;69:14–5. https://doi.org/10.1097/01.mat.0000943320.98910.40.
9. Barbu M, Hjärpe A, Martinsson A, Dellgren G, Ricksten S, Lannemyr L, et al. Cardiopulmonary bypass management and acute kidney injury in cardiac surgery patients. Acta Anaesthesiologica Scandinavica 2023;68:328–36. https://doi.org/10.1111/aas.14357.
10. Martin KR, Gamell C, Tai TY, Bonelli R, Hansen J, Tatoulis J, et al. Whole blood transcriptomics reveals granulocyte colony-stimulating factor as a mediator of cardiopulmonary bypass-induced systemic inflammatory response syndrome. Clinical & Translational Immunology 2024;13:e1490. https://doi.org/10.1002/cti2.1490.
11. Ltaief Z, Ben-Hamouda N, Rancati V, Gunga Z, Marcucci C, Kirsch M, et al. Vasoplegic Syndrome after Cardiopulmonary Bypass in Cardiovascular Surgery: Pathophysiology and Management in Critical Care. Journal of Clinical Medicine 2022;11:6407. https://doi.org/10.3390/jcm11216407.
12. Aykut G, Ulugöl H, Aksu U, Akin S, Karabulut H, Alhan C, et al. Microcirculatory Response to Blood vs. Crystalloid Cardioplegia During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. Frontiers in Medicine 2022;8:736214. https://doi.org/10.3389/fmed.2021.736214.
13. Jufar AH, Lankadeva YR, May CN, Cochrane AD, Marino B, Bellomo R, et al. Renal and cerebral hypoxia and inflammation during cardiopulmonary bypass. Comprehensive Physiology 2021;12:2799–834.

https://doi.org/10.1002/j.2040-4603.2022.tb00202.x.

14. Mittel A, Drubin C, Hua M, Nitta S, Wagener G, Melo MFV. Association of Acute Systemic Inflammation with Patient-Centric Postoperative Pulmonary Complications After Elective Cardiac Surgery. Anesthesia & Analgesia 2024;140:947–56. https://doi.org/10.1213/ane.0000000000007122.
15. Jindal P, Patil V, Pradhan R, Mahajan HC, Rani A, Pabba UG. Update on preoperative evaluation and optimisation. Indian Journal of Anaesthesia 2023;67:39–47. https://doi.org/10.4103/ija.ija_1041_22.
16. Sanders J, Makariou N, Tocock A, Magboo R, Thomas A, Aitken LM. Preoperative risk assessment tools for morbidity after cardiac surgery: a systematic review. European Journal of Cardiovascular Nursing 2022;21:655–64. https://doi.org/10.1093/eurjcn/zvac003.
17. Kontar L, Beaubien-Souligny W, Couture EJ, Jacquet-Lagrèze M, Lamarche Y, Levesque S, et al. Prolonged cardiovascular pharmacological support and fluid management after cardiac surgery. PLoS ONE 2023;18:e0285526. https://doi.org/10.1371/journal.pone.0285526.
18. Newland RF, Baker RA. Cardiopulmonary bypass parameters improve the prediction of 30-day mortality following cardiac surgery. Perfusion 2022;39:479–88. https://doi.org/10.1177/02676591221146505.
19. Chiari P, Fellahi J-L. Myocardial protection in cardiac surgery: a comprehensive review of current therapies and future cardioprotective strategies. Frontiers in Medicine 2024;11:1424188. https://doi.org/10.3389/fmed.2024.1424188.
20. Vervoort D, Caldonazo T, Doenst T, Fremes SE. Inflammatory biomarkers and cardiac surgical risk: hitting the mark? Canadian Journal of Cardiology 2023;39:1695–7. https://doi.org/10.1016/j.cjca.2023.09.004.
21. Bloc S, Alfonsi P, Belbachir A, Beaussier M, Bouvet L, Campard S, et al. Guidelines on perioperative optimization protocol for the adult patient 2023. Anaesthesia Critical Care & Pain Medicine 2023;42:101264. https://doi.org/10.1016/j.accpm.2023.101264.
22. Fu T, Jia X, Tang C, Yu D, Zhou H, Wang X, et al. Anesthetic-mediated cardioprotection: from molecular mechanisms to clinical translation challenges. Frontiers in Physiology 2025;16:1688142. https://doi.org/10.3389/fphys.2025.1688142.
23. O'Gara B, Beydoun N, Mueller A, Kumaresan A, Shaefi S. Anesthetic preferences for cardiac anesthesia: A survey of the Society of Cardiovascular Anesthesiologists. Anesthesia & Analgesia 2022;136:51–9. https://doi.org/10.1213/ane.0000000000006147.
24. Beukers A, Breel J, Van Den Brom C, Saatpoor A, Kluin J, Eleveld D, et al. Pharmacokinetics and Pharmacodynamics of analgesic and anesthetic drugs in Patients during cardiac surgery with cardiopulmonary bypass: a Narrative review. Anesthesia & Analgesia 2025;142:5–14. https://doi.org/10.1213/ane.0000000000007564.
25. Hendriks K, Forte J, Kok W, Mungroop H, Bouma HR, Scheeren TWL, et al. Mild hypothermia during cardiopulmonary bypass assisted CABG

is associated with improved short- and long-term survival, a 18-year cohort study. PLoS ONE 2022;17:e0273370. https://doi.org/10.1371/journal.pone.0273370.

26. Chen L, Xiang F, Hu Y. Corticosteroids in patients undergoing cardiac surgery: A meta-analysis of 12,559 patients. Perfusion 2022;38:853–9. https://doi.org/10.1177/02676591221106324.
27. Winterberg P, Solinsky C, Li G, Smith W. #3259 ARTEMIS: A PHASE 3 STUDY OF RAVULIZUMAB TO PROTECT PATIENTS WITH CKD UNDERGOING CARDIAC SURGERY FROM AKI AND SUBSEQUENT MAJOR ADVERSE KIDNEY EVENTS. Nephrology Dialysis Transplantation 2023;38. https://doi.org/10.1093/ndt/gfad063c_3259.
28. Bierer J, Stanzel R, Henderson M, El-Rabahi T, Sapp J, Andreou P, et al. Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem. Scientific Reports 2025;15:27643. https://doi.org/10.1038/s41598-025-11157-w.
29. Bartoszko J, Martinez-Perez S, Callum J, Karkouti K, Farouh ME, Scales DC, et al. Impact of cardiopulmonary bypass duration on efficacy of fibrinogen replacement with cryoprecipitate compared with fibrinogen concentrate: a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) randomised controlled trial. British Journal of Anaesthesia 2022;129:294–307. https://doi.org/10.1016/j.bja.2022.05.012.
30. Jenke A, Yazdanyar M, Miyahara S, Chekhoeva A, Immohr MB, Kistner J, et al. AdipoRon attenuates inflammation and impairment of cardiac function associated with cardiopulmonary Bypass–Induced systemic inflammatory response syndrome. Journal of the American Heart Association 2021;10:e018097. https://doi.org/10.1161/jaha.120.018097.
31. Guinot P-G, Desebbe O, Besch G, Guerci P, Gaudard P, Lena D, et al. Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial). American Heart Journal 2024;272:86–95. https://doi.org/10.1016/j.ahj.2024.03.008.
32. Suwalski M, Milej D, Mousseau JP, Rajaram A, Diop M, Murkin J, et al. The effect of hypotension on cerebral metabolism and perfusion in adults undergoing cardiopulmonary bypass: a Prospective cohort study. Anesthesia & Analgesia 2025;141:1067–77. https://doi.org/10.1213/ane.0000000000007607.
33. Shim J-K, Kim K-S, Couture P, Denault A, Kwak Y-L, Yoo K-J, et al. Hemodynamic management during off-pump coronary artery bypass surgery: a narrative review of proper targets for safe execution and troubleshooting. Korean Journal of Anesthesiology 2023;76:267–79. https://doi.org/10.4097/kja.23103.
34. Oh C, Lee S, Oh P, Chung W, Ko Y, Yoon S-H, et al. Comparison between Fourth-Generation FloTrac/Vigileo System and Continuous Thermodilution Technique for Cardiac Output Estimation after Time Adjustment during Off-Pump Coronary Artery Bypass Graft Surgery: A Retrospective Cohort Study. Journal of Clinical Medicine 2022;11:6093. https://doi.org/10.3390/jcm11206093.

35. Dinesen C, Vistisen ST, Aagaard R, Bisgaard SS, Juhl-Olsen P. Fourth generation FloTraC Software Pulse contour Analysis for measuring and trending Cardiac Output: A method Comparison study. Acta Anaesthesiologica Scandinavica 2025;69:e70077. https://doi.org/10.1111/aas.70077.
36. Oh C, Lee S, Oh P, Chung W, Ko Y, Yoon S-H, et al. Comparison between Fourth-Generation FloTrac/Vigileo System and Continuous Thermodilution Technique for Cardiac Output Estimation after Time Adjustment during Off-Pump Coronary Artery Bypass Graft Surgery: A Retrospective Cohort Study. Journal of Clinical Medicine 2022;11:6093. https://doi.org/10.3390/jcm11206093.
37. Goeddel LA, Koffman L, Hernandez M, Whitman G, Parikh CR, Lima JAC, et al. Occurrence of low cardiac index during normotensive periods in cardiac surgery: A prospective cohort study using continuous noninvasive cardiac output monitoring. Anesthesia & Analgesia 2024;140:77–86. https://doi.org/10.1213/ane.0000000000007206.
38. Elsebaie A, Shakeel A, Zhang S, Alarie M, Tahan ME, El-Diasty M. Effect of oxygen delivery during cardiopulmonary bypass on postoperative neurological outcomes in patients undergoing cardiac surgery: A scoping review of the literature. Perfusion 2024;40:283–94. https://doi.org/10.1177/02676591241239279.
39. Van Hoeven M, Overdevest E, Curvers J, Van Heugten H. A comparison of continuous blood gas monitors during cardiopulmonary bypass LivaNova B-Capta, Terumo CDI 500, spectrum medical M4. Perfusion 2022;38:740–6. https://doi.org/10.1177/02676591221080524.
40. Arora RC, Chatterjee S, Milewski R, Baciewicz FA, Haft J, Martin L. 2022: Perioperative and critical care year in review for the cardiothoracic surgery team. Journal of Thoracic and Cardiovascular Surgery 2024;170:279–86. https://doi.org/10.1016/j.jtcvs.2024.05.011.
41. Flinspach AN, Raimann FJ, Kaiser P, Pfaff M, Zacharowski K, Neef V, et al. Volatile versus propofol sedation after cardiac valve surgery: a single-center prospective randomized controlled trial. Critical Care 2024;28:111. https://doi.org/10.1186/s13054-024-04899-y.
42. Putowski Z, Bakker J, Kattan E, Hernández G, Ait-Oufella H, Szczeklik W, et al. Tissue perfusion as the ultimate target of hemodynamic interventions in the perioperative period. Journal of Clinical Anesthesia 2025;107:112009. https://doi.org/10.1016/j.jclinane.2025.112009.
43. Dou D, Yuan S, Jia Y, Wang Y, Li Y, Wang H, et al. The protocol of enhanced recovery after cardiac surgery in adult patients: A stepped wedge cluster randomized trial. American Heart Journal 2024;272:48–55. https://doi.org/10.1016/j.ahj.2024.02.024.
44. Malvindi PG, Bifulco O, Berretta P, Galeazzi M, Alfonsi J, Cefarelli M, et al. The Enhanced Recovery after Surgery Approach in Heart Valve Surgery: A Systematic Review of Clinical Studies. Journal of Clinical Medicine 2024;13:2903. https://doi.org/10.3390/jcm13102903.
45. Werner A, Conrads H, Rosenberger J, Creutzenberg M, Graf B, Foltan M, et al. Effects of Implementing an Enhanced Recovery After Cardiac Surgery Protocol with On-Table Extubation on Patient Outcome and Satisfaction - A

Before - After Study. Journal of Clinical Medicine 2025;14:352. https://doi.org/10.3390/jcm14020352.